Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals (IONS) — Congressional Trading Activity

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Members Trading

1

All-time in Ionis Pharmaceuticals

Buyers vs Sellers

0Buyers/0Sellers

Members buying vs selling · last 90 days

Trades (90d)

0

Disclosed in the last 90 days

Avg Member Return

—

Top performers, TTM

Stock Report
$1K - $15K
StockSaleDemocratNew YorkApr 17, 2023Mar 06, 2023House
$1K - $15K
StockSale—FloridaApr 27, 2020Jun 24, 2019House
$1K - $15K
StockPurchase—FloridaApr 27, 2020May 08, 2019House